Results

1–10 of 96 results for wet AMD

OTX-TKI for the Treatment of Neovascular Age-related Macular Degeneration 12-Month Results From a US Clinical Trial
Robert L. Avery, MD
Annual Meeting Talks
2023
Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Emmanuel Chang, MD PhD FACS FASRS
Annual Meeting Talks
2023
ENVISION Trial 24-Week Data: Phase 2 Study of UBX1325, a New Senolytic Agent for Patients With Wet AMD
Raj K. Maturi, MD
Annual Meeting Talks
2023
Safety and Efficacy of CRISPR-Based Genome Editing for Neovascular AMD
Glenn C. Yiu, MD, PhD
Annual Meeting Talks
2023
Interim Results of the Phase 1-2 PRISM Trial Evaluating 4D-150 a Dual-Transgene Intravitreal Genetic Medicine for Neovascular (Wet) Age-Related Macular Degeneration
Christine Kay, MD
Annual Meeting Talks
2023
Association Between Provider Anti-VEGF Injection Rates and Visual Outcome In Eyes With Neovascular Age-Related Macular Degeneration
Michael M. Lai, MD, PhD
Annual Meeting Talks
2024
Assessing Supplemental Injection Use Across Groups in the Phase 2 DAVIO 2 Trial of EYP-1901 vs Aflibercept in Wet Age-Related Macular Degeneration
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2024
Clinical Utility of the Fellow Eye in Patients With Bilateral GA Due to AMD: Long-Term Data from the Pegcetacoplan Clinical Program
Diana V Do, MD, FASRS
Updates from the Field
2025
Higher Order OCT Feature Assessment of the Impact of Fluid Dynamics on Visual Acuity in Neovascular AMD in a Phase III Clinical Trial: The Importance of Outer Retinal Integrity
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2022
Lady in a dress
Shelby Helton
Thomas M. Aaberg Jr. , MD
Retina Image Bank: Images of the Week
2023